Latest News and Press Releases
Want to stay updated on the latest news?
-
AT-01 is the first pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosisAT-01 visualizes and quantifies organ-specific changes in amyloid load over time AT-01 detected...
-
Final Phase 1/2 Study Results for AT-01 (Evuzamitide), Attralus's Novel Pan-Amyloid Imaging Agent for the Detection of Systemic Amyloidosis Repeat PET/CT Imaging of a Patient with Systemic Amyloidosis...
-
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of amyloidSensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in ALCardiac...
-
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
-
AT-03 potently binds human AL and ATTR fibrils and is capable of binding diverse forms of systemic amyloid deposits in mouse models AT-03 enhances macrophage-mediated phagocytosis of AL amyloid...
-
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
-
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
-
- Proceeds to advance pipeline of transformational pan-amyloid removal (PAR) therapeutics into the clinic - Financing led by Logos Capital and included other leading public healthcare funds - ...
-
SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...